FI3774859T3 - Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät - Google Patents

Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät Download PDF

Info

Publication number
FI3774859T3
FI3774859T3 FIEP19723548.4T FI19723548T FI3774859T3 FI 3774859 T3 FI3774859 T3 FI 3774859T3 FI 19723548 T FI19723548 T FI 19723548T FI 3774859 T3 FI3774859 T3 FI 3774859T3
Authority
FI
Finland
Prior art keywords
fusion protein
recombinant fusion
recombinant
protein according
nrg
Prior art date
Application number
FIEP19723548.4T
Other languages
English (en)
Finnish (fi)
Inventor
John Li
Shengwei Li
Dixiang Luo
Yiran Wu
Ming Zhou
Xiaolei Zhuang
Liang Hua
Pengyi Luo
Yang Wang
Original Assignee
Salubris Biotherapeutics Inc
Salubris Chengdu Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66484143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3774859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salubris Biotherapeutics Inc, Salubris Chengdu Biotech Co Ltd filed Critical Salubris Biotherapeutics Inc
Application granted granted Critical
Publication of FI3774859T3 publication Critical patent/FI3774859T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
FIEP19723548.4T 2018-04-11 2019-04-11 Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät FI3774859T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11
PCT/US2019/026889 WO2019200033A1 (en) 2018-04-11 2019-04-11 Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
FI3774859T3 true FI3774859T3 (fi) 2024-05-24

Family

ID=66484143

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19723548.4T FI3774859T3 (fi) 2018-04-11 2019-04-11 Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät

Country Status (26)

Country Link
US (3) US11046741B2 (cg-RX-API-DMAC7.html)
EP (2) EP4361177A3 (cg-RX-API-DMAC7.html)
JP (3) JP7575272B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260061438A (cg-RX-API-DMAC7.html)
CN (2) CN118909141A (cg-RX-API-DMAC7.html)
AU (2) AU2019252262B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020020646A2 (cg-RX-API-DMAC7.html)
CA (1) CA3096420A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002621A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020012621A2 (cg-RX-API-DMAC7.html)
DK (1) DK3774859T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092458A1 (cg-RX-API-DMAC7.html)
ES (1) ES2980163T3 (cg-RX-API-DMAC7.html)
FI (1) FI3774859T3 (cg-RX-API-DMAC7.html)
HU (1) HUE066892T2 (cg-RX-API-DMAC7.html)
IL (2) IL322374A (cg-RX-API-DMAC7.html)
MX (2) MX2020010740A (cg-RX-API-DMAC7.html)
MY (1) MY204230A (cg-RX-API-DMAC7.html)
PE (1) PE20210111A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551648A1 (cg-RX-API-DMAC7.html)
PL (1) PL3774859T3 (cg-RX-API-DMAC7.html)
PT (1) PT3774859T (cg-RX-API-DMAC7.html)
SG (1) SG11202009831UA (cg-RX-API-DMAC7.html)
TW (2) TWI888027B (cg-RX-API-DMAC7.html)
WO (1) WO2019200033A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006536B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3774859T3 (da) 2018-04-11 2024-05-27 Salubris Biotherapeutics Inc Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US12649769B2 (en) 2019-09-16 2026-06-09 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
CN114420310B (zh) * 2022-01-18 2024-11-12 河南大学 基于图转换网络的药物ATC Code预测方法
AU2023233680A1 (en) * 2022-03-15 2024-10-17 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
CN116832040B (zh) * 2023-06-12 2026-01-13 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025122581A1 (en) * 2023-12-08 2025-06-12 The Trustees Of Indiana University Compositions comprising neuregulin and methods of using the same to treat or prevent neurotrophic keratitis
TW202612723A (zh) 2024-05-21 2026-04-01 美商信立泰生物醫藥公司 神經調節蛋白-1 her3融合蛋白及其治療用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2005271902B2 (en) 2004-07-09 2011-12-08 Wayne State University Hybrid proteins with erbB4 extracellular domain and neuregulin heparin-binding domain for targeting
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
RU2010119556A (ru) 2007-10-16 2011-11-27 Симфоген А/С (Dk) Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
US20090226435A1 (en) * 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
KR20110040886A (ko) * 2008-07-08 2011-04-20 아보트 러보러터리즈 프로스타글란딘 e2 결합 단백질 및 이의 용도
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
WO2015067986A1 (en) * 2013-11-07 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuregulin allosteric anti-her3 antibody
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
TWI871999B (zh) * 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US10526416B2 (en) * 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
KR102469700B1 (ko) 2016-09-15 2022-11-23 우니베르지테트 스튜트가르트 Her3에 대한 항원 결합 단백질
DK3774859T3 (da) 2018-04-11 2024-05-27 Salubris Biotherapeutics Inc Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
ES2980163T3 (es) 2024-09-30
MX2025002112A (es) 2025-05-02
NZ768694A (en) 2024-10-25
MX2020010740A (es) 2021-01-20
IL277790B2 (en) 2026-01-01
KR20210022542A (ko) 2021-03-03
IL277790B1 (en) 2025-09-01
PE20210111A1 (es) 2021-01-19
AU2019252262B2 (en) 2023-10-05
TWI834654B (zh) 2024-03-11
AU2023285793B2 (en) 2026-01-22
TW202426470A (zh) 2024-07-01
PL3774859T3 (pl) 2024-10-14
EP4361177A2 (en) 2024-05-01
JP2025072502A (ja) 2025-05-09
CN118909141A (zh) 2024-11-08
US11046741B2 (en) 2021-06-29
DK3774859T3 (da) 2024-05-27
US20230322877A1 (en) 2023-10-12
WO2019200033A1 (en) 2019-10-17
ZA202006536B (en) 2026-04-29
JP7575272B2 (ja) 2024-10-29
US20210347841A1 (en) 2021-11-11
IL322374A (en) 2025-09-01
EP4361177A3 (en) 2024-08-14
PH12020551648A1 (en) 2021-07-26
CL2020002621A1 (es) 2021-06-11
CA3096420A1 (en) 2019-10-17
CN113166218B (zh) 2024-08-13
KR102949228B1 (ko) 2026-04-06
PT3774859T (pt) 2024-05-27
US20200010522A1 (en) 2020-01-09
JP2023134436A (ja) 2023-09-27
EP3774859B1 (en) 2024-03-13
TW201945389A (zh) 2019-12-01
EA202092458A1 (ru) 2021-02-08
TWI888027B (zh) 2025-06-21
AU2019252262A1 (en) 2020-10-22
JP7631420B2 (ja) 2025-02-18
CN113166218A (zh) 2021-07-23
KR20260061438A (ko) 2026-05-06
BR112020020646A2 (pt) 2021-02-23
HUE066892T2 (hu) 2024-09-28
IL277790A (en) 2020-11-30
JP2021535727A (ja) 2021-12-23
CO2020012621A2 (es) 2020-12-21
AU2023285793A1 (en) 2024-01-18
US11718652B2 (en) 2023-08-08
MY204230A (en) 2024-08-16
EP3774859A1 (en) 2021-02-17
SG11202009831UA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
US11357826B2 (en) IL-10 EGFR antibody fusion protein and uses thereof
AU2020201323B2 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
JP2021535727A5 (cg-RX-API-DMAC7.html)
JP7862028B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP2024016093A (ja) IgM血清半減期に影響を及ぼすIgM Fc及びJ鎖の変異
CN113166220A (zh) 创新细胞因子前药
CN112805303B (zh) 抗npr1抗体及其用途
AU2016263808A1 (en) Trispecific binding proteins and methods of use
KR20200123782A (ko) 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도
CN113166218B (zh) 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
MX2011005257A (es) Moleculas biespecificas de union a receptor de factor de crecimiento epidermial/receptor i de factor de crecimiento tipo insulina (egfr/igfir).
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
CN111375059B (zh) 一种抗gitr抗体药物组合物及其用途
EP4559932A1 (en) Multispecific antibody and use thereof
RU2652880C2 (ru) Антитело против рецептора эпидермального фактора роста
CN114316045B (zh) 抗pd-l1抗体及其用途
KR20140025836A (ko) 항 HER2/Neu 단일클론항체와 IL-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
JP2025509520A5 (cg-RX-API-DMAC7.html)
WO2022242757A1 (zh) 抗pd-1抗体的应用
JP2024534118A (ja) 抗her2抗体及びその使用方法
CN116333123A (zh) 抗tnfr2抗体及其用途
CN119798438B (zh) 一种抗ccr8单克隆抗体及其应用
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
KR20250169636A (ko) 항체 또는 이의 항원-결합 단편
WO2025157267A1 (zh) 抗pd-1-抗vegfa的双特异性抗体的医药用途